Skip to main content
Top
Published in: Clinical and Experimental Nephrology 1/2021

01-01-2021 | Systemic Lupus Erythematosus | Images in Nephrology

Zebra bodies without Fabry disease or hydroxychloroquine

Authors: Keita Kadosawa, Takashi Morikawa, Yoshio Konishi

Published in: Clinical and Experimental Nephrology | Issue 1/2021

Login to get access

Excerpt

A 29-year-old man was diagnosed with systemic lupus erythematosus (SLE) because of polyarthritis, pancytopenia, proteinuria with microhematuria, and positivity for anti-nuclear antibodies and anti-phospholipid antibody. A renal biopsy before treatment showed lupus nephritis class II + V (Fig. 1a, b, c). Glomerulosclerosis and interstitial fibrosis were scarce, and vacuolated podocytes were inconspicuous by light microscopy. However, electron microscopy revealed laminated zebra bodies in one podocyte (Fig. 1d, e), which is typical of Fabry disease [1]. The patient had no personal or family history supporting a diagnosis of Fabry disease. A-galactosidase activity was normal at 15 nmol/h/mL. Some reports show that patients with lupus nephritis develop zebra bodies after receiving hydroxychloroquine [2, 3], but our patient has not taken this drug. Although the relationship between phospholipidosis and anti-phospholipid antibodies or SLE was suggested in some case reports [4, 5], the detailed mechanism remains unknown. This is a rare case of anti-phospholipid antibody positive lupus nephritis with zebra bodies without Fabry disease or hydroxychloroquine. The cause of zebra bodies is unclear, and further investigation is needed to clarify it.
Literature
1.
go back to reference Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R. Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int. 1978;13(3):223–35.CrossRef Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R. Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int. 1978;13(3):223–35.CrossRef
2.
go back to reference Bojic M, Kozakowski N, Becede M, Kerschbaumer A, Bobacz K. The Case I Myeloid bodies in the kidney biopsy of a patient with systemic lupus erythematosus. Kidney Int. 2017;92(1):271–2.CrossRef Bojic M, Kozakowski N, Becede M, Kerschbaumer A, Bobacz K. The Case I Myeloid bodies in the kidney biopsy of a patient with systemic lupus erythematosus. Kidney Int. 2017;92(1):271–2.CrossRef
3.
go back to reference Sperati CJ, Rosenberg AZ. Hydroxychloroquine-induced mimic of renal Fabry disease. Kidney Int. 2018;94(3):634.CrossRef Sperati CJ, Rosenberg AZ. Hydroxychloroquine-induced mimic of renal Fabry disease. Kidney Int. 2018;94(3):634.CrossRef
4.
go back to reference Nandagudi A, Jury EC, Alonzi D, Butters TD, Hughes S, Isenberg DA. Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry's disease. Lupus. 2013;22(10):1070–6.CrossRef Nandagudi A, Jury EC, Alonzi D, Butters TD, Hughes S, Isenberg DA. Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry's disease. Lupus. 2013;22(10):1070–6.CrossRef
5.
go back to reference Rahman P, Gladman DD, Wither J, Silver MD. Coexistence of Fabry's disease and systemic lupus erythematosus. Clin Exp Rheumatol. 1998;16(4):475–8.PubMed Rahman P, Gladman DD, Wither J, Silver MD. Coexistence of Fabry's disease and systemic lupus erythematosus. Clin Exp Rheumatol. 1998;16(4):475–8.PubMed
Metadata
Title
Zebra bodies without Fabry disease or hydroxychloroquine
Authors
Keita Kadosawa
Takashi Morikawa
Yoshio Konishi
Publication date
01-01-2021
Publisher
Springer Singapore
Published in
Clinical and Experimental Nephrology / Issue 1/2021
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-020-01965-x

Other articles of this Issue 1/2021

Clinical and Experimental Nephrology 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.